Fulcrum Therapeutics (FULC) Net Margin (2020 - 2024)
Fulcrum Therapeutics' (FULC) quarterly Net Margin came in at 69.26% in Q2 2024, up 277187.0% year-on-year from N/an in Q3 2023, and up 101.4% on a QoQ basis from 4949.03% in Q4 2023.
Fulcrum Therapeutics (FULC) Net Margin (2020 - 2024) Analysis & Trends
Fulcrum Therapeutics (FULC) has 5 years of Net Margin data on file, last reported at 69.26% in Q2 2024.
- On a quarterly basis, Net Margin rose 277187.0% year-over-year to 69.26% in Q2 2024; TTM through Jun 2025 was 174.81%, a 8054.0% decrease from a year earlier, with the FY2024 full-year figure at 91.73%, up 969387.0% from the prior year.
- Net Margin for Q2 2024 stood at 69.26%, up from 4949.03% in the prior quarter.
- Over the last five years, Net Margin for FULC reached as high as 69.26% in Q2 2024 and fell as low as 28095.77% in Q4 2022.
- Historically, Net Margin has averaged 3881.49% across 5 years, with a median of 1954.77% in 2021.
- Across the five-year window, Net Margin tumbled 2708843 bps in 2022 and soared 2314673 bps in 2023, its largest moves.
- Year by year, Net Margin stood at 419.41% in 2020, then sank by 140 bps to 1007.34% in 2021, then tumbled by 2689 bps to 28095.77% in 2022, then jumped by 82 bps to 4949.03% in 2023, then soared by 101 bps to 69.26% in 2024.
- Per Business Quant data, the three most recent Net Margin figures were 69.26% in Q2 2024, 4949.03% in Q4 2023, and 3164.3% in Q3 2023.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,072.09 Bn | 67,072.09 Bn | - | - |
| 2 | Nanobiotix | 1,894.61 Bn | 1,894.55 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | - |
| 4 | BeOne Medicines | 471.64 Bn | 466.85 Bn | 1.35 Bn | 15.02% |
| 5 | Vertex Pharmaceuticals | 121.72 Bn | 114.47 Bn | 2.59 Bn | 34.53% |
| 6 | Regeneron Pharmaceuticals | 68.28 Bn | 59.52 Bn | 3.31 Bn | 20.17% |
| 7 | Belite Bio | 61.40 Bn | 61.40 Bn | - | - |
| 8 | Argenx Se | 56.94 Bn | 56.94 Bn | 1.18 Bn | 28.20% |
| 9 | Revolution Medicines | 37.37 Bn | 37.37 Bn | - | - |
| 10 | Fulcrum Therapeutics | 285.43 Mn | 285.43 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2024 | 69.26% |
| Dec 31, 2023 | -4,949.03% |
| Sep 30, 2023 | -3,164.30% |
| Jun 30, 2023 | -2,702.61% |
| Mar 31, 2023 | -10,346.78% |
| Dec 31, 2022 | -28,095.77% |
| Sep 30, 2022 | -2,289.43% |
| Jun 30, 2022 | -1,883.21% |
| Mar 31, 2022 | -3,626.42% |
| Dec 31, 2021 | -1,007.34% |
| Sep 30, 2021 | -1,954.77% |
| Jun 30, 2021 | -867.11% |
| Mar 31, 2021 | -477.82% |
| Dec 31, 2020 | -419.41% |
| Sep 30, 2020 | -1,026.08% |
| Jun 30, 2020 | -784.25% |
| Mar 31, 2020 | -2,460.27% |